Overview

Dexmedetomidine and the Inflammatory Response in Pediatric Cardiac Surgery

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
0
Participant gender:
All
Summary
Cardiopulmonary bypass-assisted surgery initiates a systemic inflammatory response induced by extrinsic (e.g. anesthesia, contact activation within the extracorporeal circuit, endotoxemia) and intrinsic (e.g. tissue damage, endothelial cell activation, ischemia-reperfusion injury of myocardium) factors. This may either be mild or lead to a more severe clinical condition. Inflammation after pediatric open heart surgery is a parameter affecting also duration of mechanical ventilatory support. Dexmedetomidine use was associated with a reduced increase in plasma IL-1, IL-6, TNF-a, and INF-g levels
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Assiut University
Treatments:
Dexmedetomidine
Criteria
Inclusion Elective repair of congenital heart disease with cardiopulmonary bypass Exclusion
Reintervention surgery requirement for blood products from the start of CPB, preoperative
intake of corticosteroids, deep hypothermia, those with preoperative low cardiac output,
those with non-palpable peripheral pulses before surgery (e.g., accompanying coarctation of
the aorta) or ischemic time during cardiopulmonary bypass more than 90 minutes